What Are GLP-1 Medications? A Plain-Language Guide to How They Work and Why They Matter

If you have been paying attention to the health and wellness space lately, you have almost certainly heard the terms semaglutide, tirzepatide, Ozempic, or Wegovy. GLP-1 medications have become the most-discussed development in obesity medicine in decades — and for good reason. But the conversation has also been filled with misinformation, unrealistic expectations, and oversimplification. Whether you are considering this pathway for the first time or trying to separate fact from hype, this guide is designed to give you a clear, honest, and science-backed foundation.

At Vantage Telehealth, we believe you deserve to understand exactly what is happening in your body before you make any decision about your care. Let us start at the beginning.

The Hormone Behind the Name

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the small intestine. Your body releases it in response to eating. Its primary jobs are straightforward but powerful: it signals the pancreas to release insulin when blood sugar rises, tells the liver to slow down glucose production, and — perhaps most relevant to weight management — travels to the brain to signal satiety, or the feeling of fullness.

For people living with obesity, research has shown that this satiety signaling system may not function optimally. The brain does not receive the same strength of “I am full” signal that it might in others, making it biologically harder to stop eating even when the body has taken in enough energy. This is not a willpower failure. It is physiology.

GLP-1 receptor agonist medications work by mimicking this natural hormone, binding to the same receptors and amplifying the body’s own signaling pathways. The result: reduced appetite, slower gastric emptying (food moves out of the stomach more gradually, keeping you fuller longer), improved insulin regulation, and meaningful, sustained weight loss in many patients.

A Brief History: From Diabetes Drug to Weight-Loss Breakthrough

GLP-1 receptor agonists were originally developed to treat type 2 diabetes. Researchers noticed early on that patients using these medications were losing significant weight as a secondary effect — something that stood out sharply because most diabetes medications at the time either had no effect on weight or caused weight gain.

As clinical data accumulated, the evidence for weight loss became undeniable. Liraglutide (Saxenda) became the first GLP-1 medication approved specifically for chronic weight management in 2014. The real inflection point came with the approval of semaglutide (Wegovy) in 2021 and tirzepatide (Zepbound) — a dual GIP/GLP-1 agonist — in 2023. Clinical trials backing these medications showed weight loss outcomes in the range of 15 to 22 percent of body weight, levels that had previously only been associated with bariatric surgery.

According to data published in the STEP 1 trial in the New England Journal of Medicine (Wilding et al., 2021), weekly semaglutide injections resulted in an average weight loss of approximately 14.9 percent of body weight over 68 weeks in adults with obesity, compared to roughly 2.4 percent with placebo. Tirzepatide’s SURMOUNT-1 trial (Jastreboff et al., 2022), also published in the New England Journal of Medicine, showed even more robust results, with participants on the highest dose achieving an average of 22.5 percent body weight reduction. For context, a 15 percent reduction in body weight in someone who weighs 250 pounds means losing 37 pounds — a change that carries meaningful downstream effects on metabolic health, cardiovascular risk, joint pain, sleep apnea, and overall quality of life.

How GLP-1 Medications Are Delivered

Traditionally, GLP-1 medications have been administered as weekly subcutaneous injections — a small injection placed under the skin of the abdomen, thigh, or upper arm. For many patients, the needle is far less intimidating in practice than it sounds, and the once-weekly schedule makes it relatively manageable to incorporate into daily life.

The landscape is expanding rapidly. In late 2025, the FDA approved an oral formulation of semaglutide (the Wegovy pill) for weight management — the first oral GLP-1 for obesity. In April 2026, orforglipron (brand name Foundayo) became the first oral small-molecule GLP-1 receptor agonist approved for weight management, with no food or water timing restrictions — simply a daily tablet at any time. This means patients who have avoided GLP-1 medications due to a fear of injections now have real alternatives. Your provider can help you think through what delivery method makes the most sense for your lifestyle.

Who Is a Candidate for GLP-1 Therapy?

GLP-1 medications are not appropriate for everyone, and responsible prescribing requires a thorough medical evaluation. Current FDA-approved indications for weight management typically include adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, or elevated cholesterol.

Eligibility is about far more than a number on a scale. At Vantage, every patient undergoes a comprehensive evaluation by a licensed provider who reviews medical history, current medications, underlying conditions, and personal health goals. Certain conditions — including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), active pancreatitis, and others — are contraindications. Pregnancy also requires a different approach to weight management. This is precisely why clinical evaluation is not a formality; it is a fundamental protection.

Side Effects: What to Expect

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, constipation, and diarrhea. These effects are most pronounced during the dose escalation phase — the period when your provider is gradually increasing your dose to allow your body to adjust — and they typically improve significantly over time as your system adapts.

Strategies like eating smaller meals, avoiding high-fat foods, eating slowly, and staying well hydrated can meaningfully reduce gastrointestinal discomfort. More serious side effects, including pancreatitis and gallbladder disease, are less common but important to be aware of. This is why ongoing monitoring by a licensed provider is a core part of responsible GLP-1 care — and it is why licensed providers in our partner network provide continued clinical oversight throughout your treatment, not just at your initial visit.

Beyond Weight Loss: The Expanding Promise of GLP-1 Therapy

What makes GLP-1 medications compelling from a medical perspective is not only weight loss — it is the downstream effects on overall health. The SELECT trial, published in the New England Journal of Medicine in 2023 (Lincoff et al.), showed that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20 percent in people with obesity and established cardiovascular disease, independent of weight loss. This finding suggests direct cardioprotective mechanisms beyond simply reducing obesity-related risk.

Research is also exploring GLP-1 therapy’s potential role in metabolic liver disease, chronic kidney disease, obstructive sleep apnea (tirzepatide received FDA approval for this indication in December 2024), and metabolic brain health. U.S. News and World Report’s panel of 58 medical experts named GLP-1 expansion as the top health and nutrition trend for 2026, with more than half of respondents pointing to it as the most significant development in the space.

Is GLP-1 Therapy Right for You?

That is exactly the question a licensed provider in our partner medical network is here to help you answer. Through a simple online intake process, you can share your health history, goals, and concerns — and a licensed clinician will review your information and determine whether GLP-1 therapy is an appropriate next step for your specific situation. There is no pressure, no one-size-fits-all approach, and no prescription issued unless it is clinically warranted.

If you have been curious about GLP-1 medications but were not sure where to start, this is the place. Getting started with Vantage is simpler than you might think, and it begins with a short online form you can complete from home, on your schedule. We are here when you are ready.

Learn more about GLP-1 weight loss care at Vantage

Frequently Asked Questions

What are GLP-1 medications?

GLP-1 medications are prescription treatments that mimic a natural hormone called glucagon-like peptide-1, which regulates appetite and blood sugar. They include semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). They are prescribed for type 2 diabetes and, in some cases, for chronic weight management.

How do GLP-1 drugs work?

GLP-1 medications work by signaling satiety to your brain, slowing stomach emptying, and improving insulin regulation. This reduces appetite and food intake, which supports weight loss. They also improve blood sugar control, which is why they were originally developed for type 2 diabetes.

Are GLP-1 medications safe?

GLP-1 medications have been studied extensively and are considered safe for most patients when prescribed and monitored by a licensed provider. Common side effects include nausea, constipation, and reduced appetite; serious side effects are rare. Provider screening for contraindications is important before starting.

Who is a candidate for GLP-1 weight loss medication?

Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition may be candidates for GLP-1 medications for weight management. Type 2 diabetes is a separate indication. A licensed provider evaluates candidacy individually — not everyone qualifies.

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain semaglutide, the same active ingredient. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management at a higher dose. The FDA also recently approved an oral formulation of semaglutide for weight loss.

How much does GLP-1 therapy cost?

Brand-name GLP-1 medications have list prices of roughly $1,000 or more per month without insurance, though manufacturer self-pay programs now offer lower cash prices. Compounded GLP-1 medications from state-licensed U.S. pharmacies typically cost less, but compounded medications are not FDA-approved. Vantage publishes transparent cash-pay pricing so patients know what they are paying up front.

See how Vantage Telehealth can help — Get Started →

Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or treatment program. Results vary by individual. GLP-1 medications are prescription treatments and are only prescribed when clinically appropriate by a licensed provider.